Although no clinical trials have been reported for human cancers, a recent study showed that an inhibitor of RAD52 could reduce the growth of BRCA1‐deficient tumors in mice (Sullivan‐Reed et al., 2018). This evidence concerns the gene BRCA1 and cancer.